NO983284L - Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser. - Google Patents

Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser.

Info

Publication number
NO983284L
NO983284L NO19983284A NO983284A NO983284L NO 983284 L NO983284 L NO 983284L NO 19983284 A NO19983284 A NO 19983284A NO 983284 A NO983284 A NO 983284A NO 983284 L NO983284 L NO 983284L
Authority
NO
Norway
Prior art keywords
monoclonal antibody
embolism
thrombosis
medicament
factor
Prior art date
Application number
NO19983284A
Other languages
English (en)
Other versions
NO983284D0 (no
Inventor
Michael Neal Blackburn
William Robert Church
Giora Zeev Feuerstein
Mitchell Stuart Gross
Andrew John Nichols
Eduardo Augustin Padlan
Arunbhai Haribhai Patel
Daniel Robert Sylvester
Original Assignee
Smithkline Beecham Corp
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Univ Vermont filed Critical Smithkline Beecham Corp
Publication of NO983284D0 publication Critical patent/NO983284D0/no
Publication of NO983284L publication Critical patent/NO983284L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19983284A 1996-01-17 1998-07-16 Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser. NO983284L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24
PCT/US1997/000759 WO1997026010A1 (en) 1996-01-17 1997-01-17 Anticoagulant agents useful in treatment of thrombosis

Publications (2)

Publication Number Publication Date
NO983284D0 NO983284D0 (no) 1998-07-16
NO983284L true NO983284L (no) 1998-09-16

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983284A NO983284L (no) 1996-01-17 1998-07-16 Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser.

Country Status (25)

Country Link
US (5) US6005091A (no)
EP (2) EP1832297A1 (no)
JP (2) JP2000503210A (no)
KR (1) KR100553629B1 (no)
CN (1) CN1213312A (no)
AR (1) AR005658A1 (no)
AT (1) ATE330630T1 (no)
AU (1) AU706397B2 (no)
BR (1) BR9707049A (no)
CZ (1) CZ299452B6 (no)
DE (1) DE69736197T2 (no)
DK (1) DK1007089T3 (no)
ES (1) ES2267131T3 (no)
HU (1) HU225903B1 (no)
ID (1) ID17156A (no)
IL (1) IL125380A0 (no)
MA (1) MA24512A1 (no)
MX (1) MX9805810A (no)
NO (1) NO983284L (no)
NZ (2) NZ331014A (no)
PL (1) PL187274B1 (no)
PT (1) PT1007089E (no)
SI (1) SI1007089T1 (no)
TR (1) TR199801390T2 (no)
WO (1) WO1997026010A1 (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO1999001476A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
PT1095143E (pt) * 1998-05-08 2008-11-28 Sanquin Bloedvoorziening Inibidor para o diagnóstico e tratamento de doentes com hemofilia a
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
BR9913435A (pt) * 1998-08-28 2001-09-25 Genentech Inc Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica
EP1127148B1 (en) * 1998-10-31 2012-08-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Variants of humanized anti-carcinoma monoclonal antibody cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
JP4297207B2 (ja) * 1999-07-14 2009-07-15 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 止血障害処置のための治療組成物に使用するためのリガンド
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
US7312325B2 (en) * 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
DK1222929T3 (da) 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
ES2316574T3 (es) * 2001-06-12 2009-04-16 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Anticuerpo de tipo humano contra el factor viii de la coagulacion sanguinea.
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
JP4689597B2 (ja) * 2003-03-28 2011-05-25 レセプター バイオロジックス インク． ガストリンホルモン免疫アッセイ
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (ja) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP1730193A2 (en) * 2004-03-29 2006-12-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
CA2666905A1 (en) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Method of inhibiting coagulation with human anti-factor va antibodies and use thereof
EP2197914A1 (en) 2007-09-13 2010-06-23 Delenex Therapeutics AG HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US8187591B2 (en) * 2007-10-11 2012-05-29 The Regents Of The University Of California Methods of treating coagulopathy
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
AU2013364043B2 (en) 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
CN116333144A (zh) * 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
TWI736575B (zh) * 2016-01-22 2021-08-21 美商默沙東藥廠 抗凝固因子ｘｉ抗體
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL263272B2 (en) 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
CA2143125C (en) * 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
MX9805810A (es) 1998-11-30
EP1832297A1 (en) 2007-09-12
JP2007325602A (ja) 2007-12-20
MA24512A1 (fr) 1998-12-31
CN1213312A (zh) 1999-04-07
JP2000503210A (ja) 2000-03-21
NO983284D0 (no) 1998-07-16
CZ299452B6 (cs) 2008-07-30
ES2267131T3 (es) 2007-03-01
AR005658A1 (es) 1999-07-14
US20070224198A1 (en) 2007-09-27
PT1007089E (pt) 2006-11-30
DE69736197D1 (de) 2006-08-03
KR19990077329A (ko) 1999-10-25
PL187274B1 (pl) 2004-06-30
DK1007089T3 (da) 2006-10-09
IL125380A0 (en) 1999-03-12
EP1007089A4 (en) 2003-04-16
HUP9900396A2 (hu) 1999-05-28
WO1997026010A1 (en) 1997-07-24
NZ501215A (en) 2001-04-27
CZ222598A3 (cs) 2000-01-12
ID17156A (id) 1997-12-04
AU1830897A (en) 1997-08-11
US20020146411A1 (en) 2002-10-10
HUP9900396A3 (en) 2001-10-29
US6005091A (en) 1999-12-21
EP1007089B1 (en) 2006-06-21
SI1007089T1 (sl) 2006-12-31
HK1029513A1 (en) 2001-04-06
BR9707049A (pt) 2000-10-24
HU225903B1 (en) 2007-12-28
AU706397B2 (en) 1999-06-17
ATE330630T1 (de) 2006-07-15
KR100553629B1 (ko) 2006-10-04
PL327929A1 (en) 1999-01-04
TR199801390T2 (xx) 1998-12-21
DE69736197T2 (de) 2007-06-21
NZ331014A (en) 2000-01-28
US20070003553A1 (en) 2007-01-04
US6391299B1 (en) 2002-05-21
EP1007089A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
NO983284L (no) Anvendelse av et anti-faktor 1X monoklonalt antistoff og en nukleinsyre som koder for et monoklonalt antistoff for fremstilling av et medikament for behandling av trombose- og emboli-assosierte lidelser.
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
FI955798A7 (fi) Terapeuttiset vasta-ainefrangmentit
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
NO894296D0 (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
NO911694D0 (no) Mikroemulsjonsblanding til haarbehandling, fremgangsmaate for fremstilling og anvendelse derav.
DK0666086T3 (da) Ledetråd til medicinsk formål, og fremgangsmåde til fremstilling af spiral derfor
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
FI973292A7 (fi) Substituoituja isoksatsoleja tulehduksen hoitamiseksi
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO902809L (no) Anordning og fremgangsmaate for fremstilling av syntesegass, samt anvendelse av denne.
NO904696D0 (no) Elektrostatisk, flytende fremkaller og fremgangsmaate for fremstilling av denne.
DE3889062D1 (de) Monoklonaler Antikörper gegen humanen BCDF.
DK91793D0 (da) Fremgangsmaade til overfladebehandling, midler til udoevelse og anvendelsen heraf
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
IT1305069B1 (it) Polsino per la prevenzione e il trattamento della sindrome del tunnelcarpale e metodo per la sua applicazione
NO895334D0 (no) Elektrostatisk, flytende fremkaller og fremgangsmaate for fremstilling av denne.
ITGE940100A0 (it) Procedimento e dispositivo per la produzione di un filo ritorto.
NO912368L (no) Bygning og fremgangsmaate for bygging av denne.
NO974569L (no) Benzamider for behandling av neurodegenerative forstyrrelser
NO894758L (no) Produkt med hylster og fremgangsmaate for fremstilling av produktet.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ITRM930502A0 (it) Procedimento per la produzione di r amminocarnitina e s amminocarnitina.
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application